Loading...
Market
Story
Pfizer's Ibrance Extends Survival by 15 Months in Breast Cancer Patients
Dec 12, 2024, 03:07 PM
Pfizer Inc. has announced that its drug Ibrance, which generates annual sales of $4.3 billion, has shown efficacy in extending median progression-free survival by over 15 months in a Phase 3 study for patients with HR+, HER2+ metastatic breast cancer. This development could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis. The study, known as PATINA, involved combining Ibrance with standard-of-care therapies, marking a potential expansion of its use to a new patient population that represents 10% of breast cancer cases.
View original story
Similar markets
Yes • 50%
No • 50%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
